When comparing peptides for improving body composition, two names that often come up are AOD-9604 and Tesamorelin. While both are associated with fat reduction and metabolic goals, they work in very different ways.

AOD-9604 is designed around supporting fat metabolism, while Tesamorelin works by stimulating the body’s growth hormone pathway. Choosing between them depends on your specific goals, health profile, and the type of results you are looking for.

This guide breaks down the differences between AOD-9604 and Tesamorelin, including how they work, their evidence levels, potential uses, and when each option may be considered.

AOD-9604 vs Tesamorelin: Quick Comparison

Factor

AOD-9604

Tesamorelin

Category

Fat-loss peptide

Growth hormone secretagogue

Primary role

Supports lipolysis and fat oxidation

Stimulates growth hormone release and reduces visceral fat

Mechanism

Modified growth hormone fragment activity

Activates GHRH receptors to increase natural GH pulses

Best suited for

Stubborn fat reduction and body composition goals

Visceral fat reduction, body composition improvement, and lipodystrophy

Administration

Daily subcutaneous injection

Daily subcutaneous injection

Evidence

Preclinical research and limited human studies

FDA-approved for HIV-associated lipodystrophy

Although both compounds are connected to fat reduction, they target different biological pathways.

How AOD-9604 Works

AOD-9604 is a modified fragment of human growth hormone designed to encourage fat breakdown without producing the same growth hormone effects associated with full-length GH.

Its main focus is supporting:

• Lipolysis (the breakdown of stored fat)

• Fat oxidation

• Body composition improvements

Unlike growth hormone secretagogues, AOD-9604 does not primarily work by increasing growth hormone levels. Instead, it aims to mimic some fat-metabolism effects linked to growth hormone activity.

Who May Consider AOD-9604?

AOD-9604 may be more appealing for people whose main goal is:

• Reducing stubborn fat

• Improving body composition

• Supporting fat metabolism

Individuals focused specifically on targeted fat reduction may prefer an approach centered around lipolysis rather than increasing hormone signaling.

How Tesamorelin Works

Tesamorelin works differently from AOD-9604.

It is a growth hormone-releasing hormone (GHRH) analog that activates receptors involved in natural growth hormone production. This leads to increased pulsatile growth hormone release and higher downstream activity involving insulin-like growth factor-1 (IGF-1).

Tesamorelin has been studied and approved for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.

Its effects are primarily associated with:

• Growth hormone stimulation

• Visceral fat reduction

• Body composition changes

AOD-9604 vs Tesamorelin: Which Is Better for Fat Loss?

The better option depends on what type of fat reduction you are targeting.

AOD-9604 May Be Better For:

• Stubborn fat concerns

• General body composition goals

• Supporting fat breakdown pathways

Its appeal comes from its direct focus on fat metabolism rather than increasing growth hormone levels.

Tesamorelin May Be Better For:

• Visceral fat reduction

• Growth hormone pathway stimulation

• Specific medical conditions involving abnormal fat distribution

Because Tesamorelin has FDA approval for HIV-associated lipodystrophy, it has stronger clinical evidence for certain medical applications.

Evidence Comparison: AOD-9604 vs Tesamorelin

One of the biggest differences between these peptides is the amount of available research.

AOD-9604 Evidence

Research on AOD-9604 includes:

• Laboratory studies

• Animal research

• Limited human clinical studies

The available evidence suggests potential effects on fat metabolism, but larger human trials are needed to fully understand its effectiveness.

Tesamorelin Evidence

Tesamorelin has stronger clinical support because it has been evaluated in human trials and received FDA approval for a specific medical indication.

Research has demonstrated benefits related to:

• Reduction of visceral abdominal fat

• Changes in body composition

• Growth hormone pathway activation

For medically approved applications, Tesamorelin currently has the stronger evidence profile.

Can You Use AOD-9604 and Tesamorelin Together?

Because AOD-9604 and Tesamorelin influence different pathways, some people explore combining them.

AOD-9604 focuses on fat metabolism, while Tesamorelin stimulates growth hormone signaling. Since their mechanisms are different, they may theoretically complement each other for certain body composition goals.

However, combining peptides should always involve medical guidance.

A healthcare provider can evaluate:

• Your health history

• Treatment goals

• Potential risks

• Appropriate timing and monitoring

Using multiple compounds without professional oversight may increase unnecessary risks.

Other Popular Peptides Researchers Are Exploring

Beyond AOD-9604 and Tesamorelin, several other peptides have gained attention in research communities for different purposes.

Peptide

Clinical Interest Score

Common Research Interest

BPC-157

88

Tissue repair and gut-related research

TB-500

82

Injury recovery research

Sermorelin

78

Growth hormone support

Ipamorelin

75

Recovery and hormone-related research

GHK-Cu

70

Skin and tissue repair

Interest levels do not necessarily represent proven effectiveness. The amount and quality of human evidence varies significantly between compounds.

Frequently Asked Questions

Which has stronger evidence: AOD-9604 or Tesamorelin?

Tesamorelin has stronger evidence because it has FDA approval for HIV-associated lipodystrophy and has been studied in human clinical trials.

AOD-9604 has promising research but currently has more limited clinical evidence.

Which peptide should I choose first?

The choice depends on your primary goal.

AOD-9604 may align more closely with goals focused on:

• Fat metabolism

• Stubborn fat reduction

• Body composition

Tesamorelin may be more relevant for goals involving:

• Visceral fat reduction

• Growth hormone pathway activation

• Specific medical conditions

A qualified healthcare provider can help determine which approach fits your situation.

Tips Before Considering Peptide Therapy

Before starting any peptide-related treatment, consider these steps:

1. Define Your Goal Clearly

Fat loss, visceral fat reduction, recovery, and hormone support are different goals and may require different approaches.

2. Review the Evidence

Not all peptides have the same level of research. Consider whether a compound has:

• Human clinical trials

• Regulatory approval

• Long-term safety data

3. Work With a Healthcare Professional

Medical guidance can help with:

• Selecting appropriate treatments

• Monitoring results

• Managing potential side effects

4. Focus on Lifestyle Foundations

Peptides should not replace:

• Balanced nutrition

• Resistance training

• Quality sleep

• Healthy daily habits

These factors remain essential for improving body composition.

Final Thoughts: Choosing Between AOD-9604 and Tesamorelin

AOD-9604 and Tesamorelin are often compared because both are associated with fat reduction, but they are fundamentally different compounds.

AOD-9604 is primarily focused on supporting fat metabolism and lipolysis, making it a topic of interest for body composition goals. Tesamorelin works through the growth hormone pathway and has stronger clinical evidence for reducing visceral fat in specific medical situations.

There is no universal winner between the two. The better choice depends on your goals, health history, and the level of evidence you prioritize.

Anyone considering peptide therapy should discuss options with a licensed healthcare provider to determine the safest and most appropriate approach.